REMEGEN (09995) Stock Price, News, Quotes-Moomoo

HK Stock MarketDetailed Quotes

09995 REMEGEN

Watchlist

14.600
-0.220-1.48%

Market Closed Dec 27 16:08 CST

7.95BMarket Cap-4.62P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
cls.cnDec 24 04:16 ET
RemeGen Co. Ltd. to Strengthen Leadership With New Director
TipRanksDec 23 05:07 ET
RemeGen Co. Ltd. Announces 2025 Extraordinary Meeting
TipRanksDec 23 05:07 ET
REMEGEN (09995.HK): Huang Guobin has been nominated as an independent non-executive Director candidate.
Gelonghui, December 23丨REMEGEN (09995.HK) announced that at the Board of Directors meeting to be held on December 23, 2024, Huang Guobin has been nominated as a candidate for the company's independent non-executive director.
Gelonghui FinanceDec 23 04:58 ET
RemeGen Co., Ltd. Announces H Shares Register Closure
TipRanksDec 19 06:08 ET
Express News | RemeGen Co Ltd: Safety Profile in Phase III Study of Disitamab Vedotin Was Consistent With Past Disitamab Vedotin Use Experience
ReutersDec 12 18:25 ET

Comments

Moomoo AI

Mar 22 20:21

RemeGen's high P/S ratio, driven by current investor sentiment and future expectations, may be concerning given the company's less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable.

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up

Moomoo AI

Feb 6 19:09

Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.

Some Confidence Is Lacking In RemeGen Co., Ltd. (HKG:9995) As Shares Slide 47%

ကင်ချီ

Jan 24 21:46

$REMEGEN (09995.HK)$ This shitty stock

Spinee

Jan 17 02:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

SEA Hedge

Dec 15, 2021 01:56

In FT's story, The commerce department is expected to place more than two dozen Chinese companies on the entity list on Thursday, including some involved in biotechnology.
The news triggers the sell-off in Hong Kong.
$WUXI BIO (02269.HK)$ $WUXI APPTEC (02359.HK)$ $CLOVER BIO-B (02197.HK)$ $REMEGEN (09995.HK)$